M

    Mediwound Ltd (MDWD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $12.61
    -0.05 (-0.39%)

    Market Cap: $163.44M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    57%(23/40)
    Avg Surprise
    +51.87%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.73
    Range$-0.92 - $-0.62
    5 analysts
    EPS Revisions
    4
    0
    7d
    4
    1
    30d
    EPS Estimate Drift
    90d ago$-0.75-3.6%
    60d ago$-0.71+2.8%
    30d ago$-0.71+2.8%
    7d ago$-0.71+2.8%
    Current$-0.73
    Revenue Consensus
    $7M
    Range$6M - $8M
    6 analysts
    Dec 31, 2026
    EPS Consensus$-0.07
    Range$-0.55 - $0.18
    5 analysts
    Revenue Consensus
    $11M
    Range$8M - $13M
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.07---
    Sep 26EST
    		-$-0.73---
    Jun 26
    		$-0.77$-0.76-1.32%Miss+37.4%
    Mar 26
    		$-0.23N/A+65.15%Beat-228.6%
    Dec 25
    		$-0.56$-0.61+8.20%Beat-55.6%
    Sep 25
    		$-0.24N/A+71.08%Beat+75.5%
    Jun 25
    		$-1.23$-0.57-115.79%Miss-80.9%
    Mar 25
    		$-0.07N/A+89.39%Beat+93.3%
    Dec 24
    		$-0.36$-0.59+38.98%Beat-89.5%
    Sep 24
    		$-0.98$-0.44-122.73%Miss-308.3%
    Jun 24
    		$-0.68$-0.42-61.90%Miss-780.0%
    Mar 24
    		$-1.05$-0.41-156.10%Miss-138.6%
    Dec 23
    		$-0.19$-0.23+17.39%Beat+83.9%
    Sep 23
    		$-0.24$-0.39+38.46%Beat+73.6%
    Jun 23
    		$0.10N/A+129.41%Beat+111.0%
    Mar 23
    		$-0.44$-0.43-2.33%Miss+47.6%
    Dec 22
    		$-1.18$-0.59-100.00%Miss-12.4%
    Sep 22
    		$-0.91$-0.68-33.82%Miss-8.3%
    Jun 22
    		$-0.91$-0.68-33.82%Miss-8.3%
    Mar 22
    		$-0.84$-0.76-10.53%Miss-20.0%
    Dec 21
    		$-1.05$-1.05+0.00%Beat-150.0%
    Sep 21
    		$-0.84$-0.90+6.67%Beat-71.4%
    Jun 21
    		$-0.84$-0.78-7.69%Miss-9.1%
    Mar 21
    		$-0.70$-0.81+13.58%Beat-11.1%
    Dec 20
    		$-0.42$-0.79+46.84%Beat+53.8%
    Sep 20
    		$-0.49$-0.67+26.87%Beat+36.4%
    Jun 20
    		$-0.77$-0.84+8.33%Beat-123.4%
    Mar 20
    		$-0.63$-1.00+37.00%Beat+40.0%
    Dec 19
    		$-0.91$-0.73-24.66%Miss-160.0%
    Sep 19
    		$-0.77$-0.91+15.38%Beat+0.0%
    Jun 19
    		$3.29$-0.18+1927.78%Beat+413.3%
    Mar 19
    		$-1.05$-0.98-7.14%Miss+11.8%
    Dec 18
    		$-0.35N/A+66.98%Beat+44.4%
    Sep 18
    		$-0.77$-1.37+43.80%Beat+31.3%
    Jun 18
    		$-1.05$-1.37+23.36%Beat+25.0%
    Mar 18
    		$-1.19$-0.94-26.60%Miss+15.0%
    Dec 17
    		$-0.63$-1.19+47.06%Beat+0.0%
    Sep 17
    		$-1.12$-1.33+15.79%Beat+38.5%
    Jun 17
    		$-1.40$-1.37-2.19%Miss-
    Mar 17
    		$-1.40$-1.18-18.64%Miss-
    Dec 16
    		$-0.63N/A+63.79%Beat-
    Sep 16
    		$-1.82$-1.80-1.11%Miss-

    Key Metrics

    Valuation
    P/E Ratio-7.01EV/EBITDA-6.32x
    Price/FCF-5.72xFCF Yield-17.47%
    Profitability
    Profit Margin-170.10%Operating Margin-305.90%
    ROE-72.40%ROIC-57.11%
    Financial Health
    Debt/Equity0.03xInterest CoverageN/A
    Current Ratio2.32xQuick Ratio2.09x
    Trading Statistics
    Beta0.16Avg Volume87.06K
    52-Week High$20.3052-Week Low$12.52

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$13.07
    SMA 20$13.50
    SMA 50$14.11
    SMA 200$16.35
    EMA 10$13.04
    EMA 20$13.38
    EMA 50$14.01
    EMA 200$15.80

    MACD

    Line: -0.41Signal: -0.34Hist: -0.07

    ADX

    ADX: 27.3+DI: 8.3-DI: 21.6

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down96.0
    PSAR$12.52

    Bollinger Bands

    Upper Band$14.63
    Lower Band$12.38
    %B Position1664%(Upper)
    Band Width0.10

    RSI (14-Day)

    Neutral
    33.8

    Momentum Oscillators

    Stoch %K15.0
    Stoch %D14.9
    Williams %R-95.2
    ROC (10d)-5.8%
    Momentum-0.78
    CCI (20d)-121.6
    MFI (14d)25.5

    Volatility Measures

    ATR (14d)$0.47(3.7%)
    StdDev (20d)0.56
    Hist Vol32.7%(Moderate)

    Volume Flow

    VWAP$12.71
    OBV743.2K
    AD Line-2.8M
    CMF (20d)-0.311

    Volume Metrics

    Avg Vol (20d)88.4K
    Vol Ratio1.9x(High)
    VWMA (20d)$13.27

    Pivot Points

    R3$13.71
    R2$13.45
    R1$13.05
    Pivot Point$12.79
    S1$12.39
    S2$12.13
    S3$11.73

    Advanced Oscillators

    TSI-29.12
    Ultimate Osc36.3
    KST-85.68

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$3.09M$1.48M$1.87M$5.43M$5.71M$3.96M$5.84M$4.36M$5.06M$4.96M$5.34M$4.78M
    Cost of Revenue$2.75M$1.15M$1.59M$4.53M$4.37M$3.22M$4.94M$3.68M$4.62M$4.36M$4.62M$3.88M
    Gross Profit$337,000$323,000$278,000$896,000$1.34M$738,000$903,000$677,000$447,000$607,000$719,000$896,000
    Operating Expenses$9.79M$8.30M$8.09M$7.42M$7.06M$5.96M$6.99M$5.76M$4.93M$4.34M$4.61M$3.92M
    R&D$5.90M$5.18M$4.48M$3.46M$3.49M$2.89M$2.99M$2.52M$1.90M$1.47M$1.81M$1.53M
    SG&A$0$2.30M$3.85M$2.32M$2.10M$1.79M$4.04M$2.17M$1.81M$1.69M$6.77M$1.42M
    Operating Income$-9,458,000$-7,980,000$-7,813,000$-6,525,000$-5,716,000$-5,225,000$-6,083,000$-5,081,000$-4,484,000$-3,734,000$-3,894,000$-3,025,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$1.12M$0$0$0$7.99M$0$0$5.18M$2.40M$5.97M$5.97M$0
    Income Before Tax$-7,359,000$-2,969,000$-7,110,000$-2,599,000$-13,280,000$-721,000$-3,890,000$-10,261,000$-6,307,000$-9,705,000$-1,623,000$-2,148,000
    Income Tax Expense$33,000$-17,000$73,000$53,000$38,000$5,000$18,000$21,000$-2,000$24,000$120,000$48,000
    Net Income$-7,392,000$-2,952,000$-7,183,000$-2,652,000$-13,318,000$-726,000$-3,908,000$-10,282,000$-6,305,000$-9,729,000$-1,743,000$-2,196,000
    EBITDA$-9,056,000$-2,591,000$-5,174,000$-2,181,000$-4,893,000$-363,000$-15,715,000$-4,720,000$-3,545,000$-3,366,000$5.64M$-1,809,000
    EBIT$-9,458,000$-2,969,000$-5,864,000$-2,599,000$-5,287,000$-721,000$-16,112,000$-5,081,000$-3,902,000$-3,734,000$5.29M$-2,148,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about MDWD

    Government Contracts

    Gov Obligations (TTM)
    $0
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    100.0%
    Active Awards
    1
    New Awards (TTM)
    0
    Avg Remaining Term
    N/A

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    New Research Estimates a $4 Billion Market by 2028, and MediWound Thinks It May Have a Solution (Nasdaq: MDWD)

    MediWound (Nasdaq: MDWD) is positioning its investigational biologic drug, EscharEx, to address the growing market for enzyme-based debridement in pressure ulcers, a segment estimated to reach $4 billion by 2028. New research suggests pressure ulcers represent the largest overlooked patient population in chronic wound care, with significant healthcare costs. EscharEx aims to disrupt the current treatment landscape dominated by Santyl, by offering a faster and non-surgical debridement method, with ongoing clinical trials supporting its potential efficacy.

    TradingView•8/25/26•
    Bullish

    Weekly Recap: Reaffirmed 2026 guidance and EscharEx Phase III enrollment

    MediWound Ltd. (NASDAQ:MDWD) reported H1 2026 revenue of $4.6M and an adjusted EBITDA loss of $15.3M, while reaffirming its 2026 revenue guidance of $24–26M, with most sales expected in H2. The company is also advancing a ~40-site global Phase III VALUE trial for EscharEx, targeting U.S. peak sales of approximately $1.05 billion for the treatment of venous leg ulcers. Enrollment for the trial is expected by the end of Q1 2027.

    TradingView•8/18/26•
    Neutral

    MediWound Ltd. (NASDAQ:MDWD) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

    MediWound Ltd. (NASDAQ:MDWD) exceeded analyst expectations in its second-quarter results, with revenues of US$3.1m and losses of US$0.57 per share. Analysts have moderately uplifted their sentiment, improving loss per share forecasts for 2026, though the average price target remained steady at US$29.83. The company is projected for substantial revenue growth of 298% by the end of 2026, significantly outpacing the industry average.

    Simply Wall Street•8/16/26•
    Somewhat-Bullish

    Wall Street Zen Downgrades MediWound (NASDAQ:MDWD) to Strong Sell

    Wall Street Zen has downgraded MediWound (NASDAQ:MDWD) from "sell" to "strong sell," despite the broader analyst consensus being "Hold" with an average price target of $33.00. MediWound's shares opened at $13.56, close to its 12-month low, and the company recently missed quarterly earnings expectations but exceeded revenue estimates. Insider trading and institutional investment activity show mixed signals, with a director increasing his stake and several large investors adjusting their holdings.

    MarketBeat•8/15/26•
    Bearish

    MediWound (MDWD) Stock Faces Cash Burn As Revenue Slips

    MediWound (MDWD) reported a Q2 revenue of US$3.1 million and a net loss of US$7.4 million, reflecting a revenue decline but a narrowed loss per share year-over-year. The company's cash burn and reliance on two key assets, EscharEx and NexoBrid, are concerns, despite reaffirming 2026 revenue guidance and progressing clinical timelines and government contracts. Manufacturing delays for NexoBrid and a significant reduction in H1 sales further pressure the stock, leading to recent price declines.

    Simply Wall Street•8/15/26•
    Bearish

    Frequently Asked Questions About MDWD

    Does MDWD pay dividends?
    Mediwound Ltd (MDWD) does not currently pay a regular dividend.
    What is MDWD's market cap?
    Mediwound Ltd (MDWD) has a market capitalization of $163.44M with a current stock price of $12.61.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In